US 12,168,013 B2
Antiviral prodrugs and nanoformulations thereof
Howard Gendelman, Omaha, NE (US); and Benson Edagwa, Omaha, NE (US)
Assigned to Board of Regents of the University of Nebraska, Lincoln, NE (US)
Filed by Board of Regents of the University of Nebraska, Lincoln, NE (US)
Filed on Mar. 18, 2022, as Appl. No. 17/655,483.
Application 17/655,483 is a continuation of application No. 17/303,229, filed on May 24, 2021, granted, now 11,311,547.
Application 17/303,229 is a continuation of application No. 17/301,030, filed on Mar. 22, 2021, granted, now 11,154,557, issued on Oct. 26, 2021.
Application 17/301,030 is a continuation of application No. PCT/US2019/057406, filed on Oct. 22, 2019.
Claims priority of provisional application 62/748,798, filed on Oct. 22, 2018.
Prior Publication US 2022/0211716 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5365 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 31/519 (2006.01); A61P 31/18 (2006.01)
CPC A61K 31/5365 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1641 (2013.01); A61K 31/519 (2013.01); A61P 31/18 (2018.01)] 7 Claims
OG exemplary drawing
 
1. A method of inhibiting HIV integrase in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising:
a) a compound of formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein R is a saturated linear aliphatic chain of a length of 17 carbons, and
b) a pharmaceutically acceptable carrier.